Products
Research Areas
COVID-19
Resources
Login
Quick Order
Cart Cart lightblue
Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Contact Us

Locations


Orders Processing,
Shipping & Receiving,
Warehouse

2 Shaker Rd Suites
B001/B101
Shirley, MA 01464


Production Lab

Floor 6, Suite 620
20700 44th Avenue W
Lynnwood, WA 98036

Telephone Numbers



Tel: +1 (206) 374-1102
Fax: +1 (206) 577-4565

Contact Us



Additional Contact Details

Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Catalog Number Size Price
LS-B192-50 50 µg (0.5 mg/ml) $485 
CAV1 / Caveolin 1 Antibody - Human Uterus: Formalin-Fixed, Paraffin-Embedded (FFPE)
CAV1 / Caveolin 1 Antibody - Human Prostate: Formalin-Fixed, Paraffin-Embedded (FFPE)
CAV1 / Caveolin 1 Antibody - Human Lung: Formalin-Fixed, Paraffin-Embedded (FFPE)
CAV1 / Caveolin 1 Antibody - CAV1 / Caveolin 1 antibody immunofluorescence analysis of paraformaldehyde fixed U2OS cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml), showing Golgi and cytoplasmic staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml).
CAV1 / Caveolin 1 Antibody - CAV1 / Caveolin 1 antibody immunofluorescence analysis of paraformaldehyde fixed A431 cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml), showing Golgi and membrane staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml).
CAV1 / Caveolin 1 Antibody - CAV1 / Caveolin 1 antibody (0.01µg/ml) staining of Human Spleen lysate (35µg protein in RIPA buffer). Detected by chemiluminescence.
CAV1 / Caveolin 1 Antibody - CAV1 / Caveolin 1 antibody (0.003µg/ml) staining of Human Heart lysate (35µg protein in RIPA buffer). Detected by chemiluminescence.
CAV1 / Caveolin 1 Antibody - CAV1 / Caveolin 1 antibody (0.003µg/ml) staining of A431 (A) and (0.001ug/ml) A549 cell lysate (35µg protein in RIPA buffer). Detected by chemiluminescence.
CAV1 / Caveolin 1 Antibody - CAV1 / Caveolin 1 antibody flow cytometric analysis of paraformaldehyde fixed HeLa cells (blue line), permeabilized with 0.5% Triton. Primary incubation overnight (10ug/ml) followed by Alexa Fluor 488 secondary antibody (1ug/ml). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.
CAV1 / Caveolin 1 Antibody - Human Uterus: Formalin-Fixed, Paraffin-Embedded (FFPE)
CAV1 / Caveolin 1 Antibody - Human Prostate: Formalin-Fixed, Paraffin-Embedded (FFPE)
CAV1 / Caveolin 1 Antibody - Human Lung: Formalin-Fixed, Paraffin-Embedded (FFPE)
CAV1 / Caveolin 1 Antibody - CAV1 / Caveolin 1 antibody immunofluorescence analysis of paraformaldehyde fixed U2OS cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml), showing Golgi and cytoplasmic staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml).
CAV1 / Caveolin 1 Antibody - CAV1 / Caveolin 1 antibody immunofluorescence analysis of paraformaldehyde fixed A431 cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml), showing Golgi and membrane staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml).
CAV1 / Caveolin 1 Antibody - CAV1 / Caveolin 1 antibody (0.01µg/ml) staining of Human Spleen lysate (35µg protein in RIPA buffer). Detected by chemiluminescence.
CAV1 / Caveolin 1 Antibody - CAV1 / Caveolin 1 antibody (0.003µg/ml) staining of Human Heart lysate (35µg protein in RIPA buffer). Detected by chemiluminescence.
CAV1 / Caveolin 1 Antibody - CAV1 / Caveolin 1 antibody (0.003µg/ml) staining of A431 (A) and (0.001ug/ml) A549 cell lysate (35µg protein in RIPA buffer). Detected by chemiluminescence.
CAV1 / Caveolin 1 Antibody - CAV1 / Caveolin 1 antibody flow cytometric analysis of paraformaldehyde fixed HeLa cells (blue line), permeabilized with 0.5% Triton. Primary incubation overnight (10ug/ml) followed by Alexa Fluor 488 secondary antibody (1ug/ml). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.
1 of 9
2 of 9
3 of 9
4 of 9
5 of 9
6 of 9
7 of 9
8 of 9
9 of 9

PathPlus™ Polyclonal Goat anti‑Human CAV1 / Caveolin 1 Antibody (aa73‑84, IHC, IF, WB) LS‑B192

PathPlus™ Polyclonal Goat anti‑Human CAV1 / Caveolin 1 Antibody (aa73‑84, IHC, IF, WB) LS‑B192

Note: This antibody replaces LS-C20137, LS-C78001
Antibody:
CAV1 / Caveolin 1 Goat anti-Human Polyclonal (aa73-84) Antibody
Application:
IHC-P, IF, WB, Peptide-ELISA
Reactivity:
Human, Monkey
Format:
Unconjugated, Unmodified
Price
Catalog Number
$485
LS-B192-50
Toll Free North America
206-374-1102
For Research Use Only

Overview

Antibody:
CAV1 / Caveolin 1 Goat anti-Human Polyclonal (aa73-84) Antibody
Application:
IHC-P, IF, WB, Peptide-ELISA
Reactivity:
Human, Monkey
Format:
Unconjugated, Unmodified

Specifications

Description
CAV1 is a scaffolding protein encoded that is a primary component of caveolae plasma membranes in most cell types. CAV1 plays an important role in cell metabolism and is involved in autophagy, fatty acid metabolism, glutaminolysis, glycolysis and mitochondrial bioenergetics. Mutations in this gene have been associated with Berardinelli-Seip congenital lipodystrophy. In cancer, CAV1 can be a driver of tumorigenesis and also a suppressor in different contexts. For example, it appears to have an oncogenic role and may be an effective target of therapy in triple negative breast cancer with aberrant TP53 expression. Conversely, higher expression of CAV1 in some liver cancer patients is associated with improved survival, and loss of CAV1 alongside APC knockout has been shown to increase colorectal tumorigenesis. In immunohistochemistry of normal tissue, it has membranous positivity in endothelial cells, adipocytes, as well as pneumocytes and basal cells of squamous epithelia in various tissues throughout the body. References: The UniProt Consortium. Nucleic Acids Res. 47: D506-515 (2019); Nucleic Acids Res. 2016 Jan 4;44(D1):D733-45, PMID:26553804; Onco Targets Ther. 2019; 12: 1539–1552, PMID: 30881011; Mol Cancer 15, 71 (2016), DOI:10.1186/s12943-016-0558-7; Journal of Clinical Oncology 2015 33:28_suppl, 134-134, DOI: 10.1200/jco.2015.33.28_suppl.134;
Target
Human CAV1 / Caveolin 1
Synonyms
CAV1 | Caveolin-1 | CGL3 | CAV | MSTP085 | VIP21 | BSCL3
Host
Goat
Reactivity
Human, Monkey (tested or 100% immunogen sequence identity)
Clonality
Polyclonal
Conjugations
Unconjugated
Purification
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Modifications
Unmodified
Immunogen
Peptide with sequence C-DELSEKQVYDAH, from the internal region of the protein sequence according to NP_001744.2NP_001166366.1.
Epitope
aa73-84
Specificity
Human CAV1 / Caveolin. No cross-reactivity expected to Caveolin 2 and Caveolin 3
Applications
  • IHC - Paraffin (2.5 µg/ml)
  • Immunofluorescence (10 µg/ml)
  • Western blot (0.00 - 0.01 µg/ml)
  • Peptide Enzyme-Linked Immunosorbent Assay (1:8000)
Performing IHC? See our complete line of Immunohistochemistry Reagents including antigen retrieval solutions, blocking agents ABC Detection Kits and polymers, biotinylated secondary antibodies, substrates and more.
Usage
Immunohistochemistry: LS-B192 was validated for use in immunohistochemistry on a panel of 21 formalin-fixed, paraffin-embedded (FFPE) human tissues after heat induced antigen retrieval in pH 6.0 citrate buffer. After incubation with the primary antibody, slides were incubated with biotinylated secondary antibody, followed by alkaline phosphatase-streptavidin and chromogen. The stained slides were evaluated by a pathologist to confirm staining specificity. The optimal working concentration for LS-B192 was determined to be 2.5 ug/ml.
Presentation
TBS, pH 7.3, 0.02% Sodium Azide, 0.5% BSA
Storage
Aliquot and store at -20°C. Avoid freeze-thaw cycles.
Restrictions
For research use only. Intended for use by laboratory professionals.
Guarantee
This antibody carries the LSBio 100% Guarantee.
LSBio Guarantee
About CAV1 / Caveolin 1
Q03135 NM_001753 NP_001744.2

Validation

CAV1 / Caveolin 1 Antibody - Human Uterus: Formalin-Fixed, Paraffin-Embedded (FFPE)
Human Uterus: Formalin-Fixed, Paraffin-Embedded (FFPE)
Human Uterus: Formalin-Fixed, Paraffin-Embedded (FFPE)

CAV1 / Caveolin 1 Antibody - Human Prostate: Formalin-Fixed, Paraffin-Embedded (FFPE)
Human Prostate: Formalin-Fixed, Paraffin-Embedded (FFPE)
Human Prostate: Formalin-Fixed, Paraffin-Embedded (FFPE)

CAV1 / Caveolin 1 Antibody - Human Lung: Formalin-Fixed, Paraffin-Embedded (FFPE)
Human Lung: Formalin-Fixed, Paraffin-Embedded (FFPE)
Human Lung: Formalin-Fixed, Paraffin-Embedded (FFPE)

LSBio Ratings

PathPlus™ CAV1 / Caveolin 1 Antibody (aa73-84) for IHC, IF/Immunofluorescence, WB/Western LS-B192 has an LSBio Rating of
Publications (4)
Laboratory Validation Score (5)

Publications (1)

A Frame-Shift Mutation in CAV1 Is Associated with a Severe Neonatal Progeroid and Lipodystrophy Syndrome. Schrauwen I, Szelinger S, Siniard AL, Kurdoglu A, Corneveaux JJ, Malenica I, Richholt R, Van Camp G, De Both M, Swaminathan S, Turk M, Ramsey K, Craig DW, Narayanan V, Huentelman MJ. PloS one. 2015 10:e0131797. (WB; Human)

Customer Reviews (0)


Request SDS/MSDS

To request an SDS/MSDS form for this product, please contact our Technical Support department at:

Technical.Support@LSBio.com

Requested From: United States
Date Requested: 7/18/2024